Voyager Technologies Inc. has announced a new contract with Space LiinTech to deliver a payload to the International Space Station (ISS) aimed at advancing microgravity-enabled drug discovery. Under the agreement, Voyager will provide mission integration, payload configuration support, and end-to-end guidance to ensure the safe operation of Space LiinTech’s research aboard the ISS. The mission will focus on evaluating the effects of microgravity on protein crystallization, with the goal of improving drug formulations. The payload will also test an AI-driven automation and monitoring system and verify the stability and reliability of Space LiinTech’s new research module from launch to return.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Voyager Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260122524590) on January 22, 2026, and is solely responsible for the information contained therein.
Comments